FOGHORN THERAPEUTICS INC (FHTX) Stock Price, Quote, News and Overview
NASDAQ:FHTX - Nasdaq - US3441741077 - Common Stock
FHTX Quote and Key Statistics
FOGHORN THERAPEUTICS INC
NASDAQ:FHTX (1/22/2025, 10:26:21 AM)
4.29
-0.12 (-2.72%)
FHTX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FHTX Performance and Technical Analysis
FHTX Ownership and Analysts
FHTX Latest News and Analysis
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients...
FHTX Makes Notable Cross Below Critical Moving Average
About FHTX
Company Profile
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-23. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The firm is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. The company is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
Company Info
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139 US
CEO: Adrian Gottschalk
Employees: 116
Company Website: https://foghorntx.com/
Investor Relations: https://ir.foghorntx.com/
Phone: 16175863100
FHTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 300.22B | ||
| AMGN | AMGEN INC | 14.24 | 147.10B | ||
| GILD | GILEAD SCIENCES INC | 20.8 | 114.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 843.75 | 110.82B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.25B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.99B | ||
| NTRA | NATERA INC | N/A | 22.48B | ||
| BIIB | BIOGEN INC | 8.72 | 20.76B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.87B |